Novel extended quadruplet induction regimens—challenging the need for upfront high-dose therapy in newly diagnosed all-risk multiple myeloma patients

Klaus Podar

Novel extended quadruplet induction regimens—challenging the need for upfront high-dose therapy in newly diagnosed all-risk multiple myeloma patients

Research output: Journal article (peer-reviewed) › Review article

Original language	English
Journal	AME Clinical Trials Review
Publication status	Published - 07 Apr 2025

Access to Document

https://actr.amegroups.org/issue/publishAheadOfPrint.

Cite this

@article{171ad9a18fcf4d6ea81bd25e487c67be,

title = "Novel extended quadruplet induction regimens—challenging the need for upfront high-dose therapy in newly diagnosed all-risk multiple myeloma patients",

author = "Klaus Podar",

year = "2025",

month = apr,

day = "7",

language = "English",

journal = "AME Clinical Trials Review ",

issn = "3005-6152",

}

Novel extended quadruplet induction regimens—challenging the need for upfront high-dose therapy in newly diagnosed all-risk multiple myeloma patients

Access to Document

Other files and links

Cite this